C A Schiffer1, R Dodge, R A Larson. 1. Greenebaum Cancer Center (formerly University of Maryland Cancer Center), Baltimore, USA.
Abstract
BACKGROUND: During the past 3 decades, the Cancer and Leukemia Group B (CALGB) has conducted numerous large clinical trials in adult patients with acute myeloid leukemia. METHODS: Updated data were obtained for 9 trials initiated by the CALGB between 1974 and 1992. The updated data were compared with the original published results. RESULTS: It was apparent from all the studies that hazard rates for death and relapse are greatest in the first year, decrease substantially between Years 1 and 2, then decrease further between Years 2 and 3. Rates of death and relapse are quite low after 3-4 years. Large numbers of patients are long-term disease free survivors. Overall, these patients have excellent function and a normal quality of life. CONCLUSIONS: Patients with AML who are in complete remission for 3-4 years can be assured that late relapse and death are relatively uncommon events. It is inadvisable to publish results of large studies until this minimal level of follow-up has been reached.
RCT Entities:
BACKGROUND: During the past 3 decades, the Cancer and Leukemia Group B (CALGB) has conducted numerous large clinical trials in adult patients with acute myeloid leukemia. METHODS: Updated data were obtained for 9 trials initiated by the CALGB between 1974 and 1992. The updated data were compared with the original published results. RESULTS: It was apparent from all the studies that hazard rates for death and relapse are greatest in the first year, decrease substantially between Years 1 and 2, then decrease further between Years 2 and 3. Rates of death and relapse are quite low after 3-4 years. Large numbers of patients are long-term disease free survivors. Overall, these patients have excellent function and a normal quality of life. CONCLUSIONS:Patients with AML who are in complete remission for 3-4 years can be assured that late relapse and death are relatively uncommon events. It is inadvisable to publish results of large studies until this minimal level of follow-up has been reached.
Authors: John R Wingard; Navneet S Majhail; Ruta Brazauskas; Zhiwei Wang; Kathleen A Sobocinski; David Jacobsohn; Mohamed L Sorror; Mary M Horowitz; Brian Bolwell; J Douglas Rizzo; Gérard Socié Journal: J Clin Oncol Date: 2011-04-04 Impact factor: 44.544
Authors: Sebastian E Koschade; Jan A Stratmann; Fabian Finkelmeier; Sebastian Wagner; Jörg Chromik; Björn Steffen; Hubert Serve; Christian H Brandts; Olivier Ballo Journal: Ann Hematol Date: 2022-05-20 Impact factor: 4.030